Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00297570

Enrollment

Registered

2006-02-28

Start date

2006-02-28

Completion date

Unknown

Last updated

2007-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Myeloid, Philadelphia-Positive

Keywords

CML, Imatinib, Pegylated Interferon, Philadelphia Positive CML

Brief summary

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.

Interventions

DRUGPegylated Interferon and Imatinib

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of imatinib therapy.

Exclusion criteria

* Patients in imatinib study * Patients with a history of intolerability to interferon. * Patients with less than CCR or less than one year of imatinib therapy.

Countries

Israel

Contacts

Primary ContactIzhar Hardan, MD

izhar.hardan@sheba.health.gov.il+972 3 5302174

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026